Kymera Therapeutics, Inc. (KYMR)
73.91
-0.22
(-0.30%)
USD |
NASDAQ |
Jun 08, 16:00
73.97
+0.06
(+0.08%)
After-Hours: 20:00
Kymera Therapeutics EPS Diluted (Quarterly) : -0.7098 for March 31, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Revolution Medicines, Inc. | -2.291 |
| Erasca, Inc. | -0.6028 |
| Arrowhead Pharmaceuticals, Inc. | -0.932 |
| Sarepta Therapeutics, Inc. | 2.878 |
| Vir Biotechnology, Inc. | -0.853 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -69.23M |
| Revenue (Quarterly) | 34.36M |
| Total Expenses (Quarterly) | 103.60M |
| Enterprise Value | 5.522B |
| Gross Profit Margin (Quarterly) | 94.12% |
| Profit Margin (Quarterly) | -201.5% |
| Earnings Yield | -4.83% |
| Normalized Earnings Yield | -4.790 |